TAKEDA PHARMACEUTICAL CO LTD (TAK) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $5.3M sold). Latest close $21.27 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 4, 2026 · Congress to Nov 16, 2026.
Pzena Investment Management — 1 tracked fund hold TAK. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 5 sales ($5.3M). Insider trading
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Pzena Investment Management | <0.01% | 37,820 | ADDED (+33.4%) Q3 filed Oct 30 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +35.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 377 of 8,857 filers |
| Long-only filers among them | 375 |
| Change vs 2026 Q1 | +20 net · 356 entered · 336 exited |
| Shares reported, all filers | 104,137,768 |
| Reported value, all filers | $1.7B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | 4,581.6B JPY |
| Net income · FY2025 | 108.1B JPY |
| Total assets · FY2025 | 14,248.3B JPY |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026.
| Shares short · Oct 15, 2026 | 3,289,262 |
| Days to cover | 1.09 |
Shares short at recent settlements — Jul 31, 2026: 2.9M · Aug 14, 2026: 3.0M · Aug 31, 2026: 4.1M · Sep 15, 2026: 4.2M · Sep 30, 2026: 2.9M · Oct 15, 2026: 3.3M.
Source: FINRA Equity Short Interest (biweekly settlement data).
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 5 sales by 4 insiders ($5.3M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Platford Giles Richard | President, IBU | Sell | 55,617 | $20.90 | $1.2M | SEC filing |
| Nov 2, 2026 | Bitetti Teresa Marie | President, OBU | Sell | 46,609 | $20.89 | $973.7K | SEC filing |
| Sep 14, 2026 | Duprey Lauren Rusckowski | Chief Transformation Officer | Sell | 34,535 | $18.54 | $640.3K | SEC filing |
| Sep 2, 2026 | Plump Andrew Stewart | President, R&D | Sell | 116,191 | $18.49 | $2.1M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Lauren Rusckowski Duprey | Chief Transformation Officer | 34,535 | $634.4K | Sep 10, 2026 | SEC filing |
| Sep 2, 2026 | Plump Andrew Stewart | Officer | 116,191 | $2.1M | Sep 2, 2026 | SEC filing |
| Aug 19, 2026 | Plump Andrew Stewart | Officer | 19,651 | $363.3K | Aug 19, 2026 | SEC filing |
| Aug 14, 2026 | Nicola Greenway | Chief Human Resources Officer | 12,980 | $225.7K | Aug 14, 2026 | SEC filing |
| Aug 10, 2026 | Elaine Shannon | President, Global Supply & Quality | 20,363 | $355.3K | Aug 11, 2026 | SEC filing |
| Aug 6, 2026 | Nicola Greenway | Chief Human Resources Officer | 34,603 | $578.6K | Aug 7, 2026 | SEC filing |
| Jul 13, 2026 | Marcello Pignagnoli Agosti | Interim Head, Strategy and Portfolio Development | 24,887 | $416.9K | Jul 13, 2026 | SEC filing |
| Jul 13, 2026 | Lauren Rusckowski Duprey | Chief Transformation Officer | 51,579 | $863.9K | Jul 13, 2026 | SEC filing |
| Jul 13, 2026 | Giles Platford | President, International Business Unit | 33,696 | $564.4K | Jul 13, 2026 | SEC filing |
| Jul 13, 2026 | Natalie Furney | Global General Counsel | 33,454 | $560.4K | Jul 13, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· 52-Week High — Recently printed a new 52-week high
· Top Relative Strength — Top 20% of the universe by 6-month return
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold TAK — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
No Form 8-K filings for this ticker in the index (Jan 2023 – present).
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on TAK
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.